Altimmune, Inc. (ALT) research
Altimmune, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.73
- As of
Altimmune, Inc. (ALT): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
As of . Source: SEC EDGAR filings for ALT. Method and limitations.
Share the ALT intelligence card
See the full ALT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ALT on one page. Preview it with sample data, then open it live with a free account.
Preview the ALT dossierActive signals for ALT
- highCONSENSUS_BUY
4 tracked funds increased ALT this 2026Q2, institutional consensus
- mediumNEW_POSITION
VIKING GLOBAL INVESTORS LP new position in ALT
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in ALT
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 78% of ALT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +70% to ALT (2026Q2)
FREE, NO ACCOUNT
Every signal on ALT, as it fires
You are seeing 5 of 13 signals recorded on ALT since 2026-05-26.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ALT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 02155H200 · 2026Q2 | $20.4M | 0.06% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 02155H200 · 2026Q2 | $10.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 02155H200 · 2026Q2 | $7.2M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 02155H200 · 2026Q2 | $3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 02155H200 · 2026Q2 | $1.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 02155H200 · 2026Q2 | $613K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 02155H200 · 2026Q2 | $218K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ALT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ALT against its peers
ALT's operating margin of -230461.0% ranks in the 3rd percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ALT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 41000 USD | 72.3M USD | 28 | 19 |
| Operating margin | -230461.0% | -59.1% | 3 | 15 |
| Net margin | -214861.0% | -66.0% | 3 | 15 |
| Return on equity | -39.2% | -34.2% | 40 | 20 |
Peers (23): PRME, CAPR, YDES, NGNE, CBIO, VALN, ALLO, MNPR, MPLT, OCS, EPRX, PBYI, CTMX, CRMD, PHAT, AUTL, RGNX, ARVN, CTNM, OVID, IRWD, ZVRA, ASMB. Left out: RLFTY (no annual filing), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ALT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ALT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ALTand get the insider, 13F, options, and confluence read in one view.